MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 540257 | Name: Ketanserin
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ketanserin is a 5-HT2A receptor antagonist and potential α1-adrenergic receptor antagonist used to treat hypertension. It decreases blood pressure, improves left ventricular remodeling, increases capillary density in myocardial tissue, and may suppress TRPV1 channel-evoked thermal hyperalgesia.

Chemical Structure

Ketanserin
Ketanserin
CAS#74050-98-9 (free base)

Theoretical Analysis

MedKoo Cat#: 540257

Name: Ketanserin

CAS#: 74050-98-9 (free base)

Chemical Formula: C22H22FN3O3

Exact Mass: 395.1645

Molecular Weight: 395.43

Elemental Analysis: C, 66.82; H, 5.61; F, 4.80; N, 10.63; O, 12.14

Price and Availability

Size Price Availability Quantity
100mg USD 150.00 Ready to ship
200mg USD 250.00 Ready to ship
500mg USD 450.00 Ready to ship
1g USD 750.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
83846-83-7 (tartrate) 74050-98-9 (free base)
Synonym
Ketanserin; R 41468; R-41468; R41468;
IUPAC/Chemical Name
3-(2-(4-(4-fluorobenzoyl)piperidin-1-yl)ethyl)quinazoline-2,4(1H,3H)-dione
InChi Key
FPCCSQOGAWCVBH-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
SMILES Code
O=C(N1CCN2CCC(C(C3=CC=C(F)C=C3)=O)CC2)NC4=C(C=CC=C4)C1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#C21B10B20
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Ketanserin is a selective 5-HT2 receptor antagonist that also blocks hERG current (IhERG) in a concentration-dependent manner (IC50=0.11 μM).
In vitro activity:
Cells were treated with 5-HT (1 µM 5-HT hydrochloride was added to the cell culture medium) or with both 5-HT and ketanserin (5-HT+K; 0.1 μM ketanserin was added 30 minutes before the addition of 5-HT) for 72 hours. In addition to the enhanced expression of α-SMA mRNA in PFs (portal fibroblast), the phosphorylation of smad2/3 and the expression of collagen I, collagen III, and α-SMA protein increased after 72 hours of culture. Ketanserin significantly decreased the phosphorylation of smad2 and smad3 by 52% and 58%, respectively, and reduced the expression of collagen I and collagen III protein by 63% and 56%, respectively; this was concurrent with 63% and 76% decreases in α-SMA mRNA and protein expression. The transdifferentiation of PFs into MFs was also suppressed because α-SMA–positive cells were notably reduced 72 hours after ketanserin administration. The results indicated that ketanserin inhibited 5-HT–activated TGF-β1–smad2/3 signaling in vitro and thereby depressed the MF conversion of PFs. Reference: Liver Transpl. 2014 Nov;20(11):1317-26. https://pubmed.ncbi.nlm.nih.gov/25045122/
In vivo activity:
To investigate whether ketanserin reduces susceptibility to colitis, colitis was induced in mice using DSS. The mice with DSS-induced colitis exhibited a continuous decrease in body weight from day 4 to day 7 and shortened colon lengths. By contrast, the administration of ketanserin during the induction of colitis significantly prevented the decrease in body weight and colon shortening. A histological examination of the colons of the mice with DSS-induced colitis revealed severe inflammation with ulcerative lesions, loss of crypts and the infiltration of inflammatory cells, whereas treatment with ketanserin alleviated these histological changes and damage to the colon, characterized by a decrease in the loss of architecture, fewer ulcerative lesions, and a decrease in inflammatory cell infiltration into the inflamed mucosa. The data therefore suggest that ketanserin exerts a potent therapeutic effect, ameliorating DSS-induced colitis. Reference: Int J Mol Med. 2016 Mar;37(3):659-68. https://pubmed.ncbi.nlm.nih.gov/26865503/
Solvent mg/mL mM
Solubility
DMSO 16.7 42.16
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 395.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Bergqvist D, Arvidsson S, Haglund U, Hedner U, Lindblad B. The influence of ketanserin on hemostasis in vitro. Thromb Res. 1986 Jul 15;43(2):237-41. doi: 10.1016/0049-3848(86)90065-4. PMID: 2943051. 2. Chen L, Chen G, Guo Y, Liu L, Xiao L, Fan W, Shi B, Qian Y. Ketanserin, a serotonin 2A receptor antagonist, alleviates ischemia-related biliary fibrosis following donation after cardiac death liver transplantation in rats. Liver Transpl. 2014 Nov;20(11):1317-26. doi: 10.1002/lt.23947. PMID: 25045122. 3. Xiao J, Shao L, Shen J, Jiang W, Feng Y, Zheng P, Liu F. Effects of ketanserin on experimental colitis in mice and macrophage function. Int J Mol Med. 2016 Mar;37(3):659-68. doi: 10.3892/ijmm.2016.2486. Epub 2016 Feb 10. PMID: 26865503; PMCID: PMC4771115. 4. Liu C, Zhang X, Zhou JX, Wei W, Liu DH, Ke P, Zhang GF, Cai GJ, Su DF. The protective action of ketanserin against lipopolysaccharide-induced shock in mice is mediated by inhibiting inducible NO synthase expression via the MEK/ERK pathway. Free Radic Biol Med. 2013 Dec;65:658-666. doi: 10.1016/j.freeradbiomed.2013.07.045. Epub 2013 Aug 13. PMID: 23954471.
In vitro protocol:
1. Bergqvist D, Arvidsson S, Haglund U, Hedner U, Lindblad B. The influence of ketanserin on hemostasis in vitro. Thromb Res. 1986 Jul 15;43(2):237-41. doi: 10.1016/0049-3848(86)90065-4. PMID: 2943051. 2. Chen L, Chen G, Guo Y, Liu L, Xiao L, Fan W, Shi B, Qian Y. Ketanserin, a serotonin 2A receptor antagonist, alleviates ischemia-related biliary fibrosis following donation after cardiac death liver transplantation in rats. Liver Transpl. 2014 Nov;20(11):1317-26. doi: 10.1002/lt.23947. PMID: 25045122.
In vivo protocol:
1. Xiao J, Shao L, Shen J, Jiang W, Feng Y, Zheng P, Liu F. Effects of ketanserin on experimental colitis in mice and macrophage function. Int J Mol Med. 2016 Mar;37(3):659-68. doi: 10.3892/ijmm.2016.2486. Epub 2016 Feb 10. PMID: 26865503; PMCID: PMC4771115. 2. Liu C, Zhang X, Zhou JX, Wei W, Liu DH, Ke P, Zhang GF, Cai GJ, Su DF. The protective action of ketanserin against lipopolysaccharide-induced shock in mice is mediated by inhibiting inducible NO synthase expression via the MEK/ERK pathway. Free Radic Biol Med. 2013 Dec;65:658-666. doi: 10.1016/j.freeradbiomed.2013.07.045. Epub 2013 Aug 13. PMID: 23954471.
1: Singh S, Dinesh N, Kaur PK, Shamiulla B. Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani. Parasitol Res. 2014 Jun;113(6):2161-8. doi: 10.1007/s00436-014-3868-y. Epub 2014 Apr 12. PubMed PMID: 24728519. 2: Bijvank SW, Visser W, Duvekot JJ, Steegers EA, Edens MA, Roofthooft DW, Vulto AG, Hanff LM. Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015 Jun;189:106-11. doi: 10.1016/j.ejogrb.2015.02.002. Epub 2015 Mar 10. PubMed PMID: 25892082. 3: Chen L, Chen G, Guo Y, Liu L, Xiao L, Fan W, Shi B, Qian Y. Ketanserin, a serotonin 2A receptor antagonist, alleviates ischemia-related biliary fibrosis following donation after cardiac death liver transplantation in rats. Liver Transpl. 2014 Nov;20(11):1317-26. doi: 10.1002/lt.23947. PubMed PMID: 25045122. 4: Wang D, Zhou X, Hong Y. Effects of a combination of ketanserin and propranolol on inflammatory hyperalgesia in rats. Eur J Pharmacol. 2013 Dec 5;721(1-3):126-32. doi: 10.1016/j.ejphar.2013.09.043. Epub 2013 Sep 25. PubMed PMID: 24076184. 5: Miryala CS, Hiegel C, Uphouse L. Comparison of female Fischer and Sprague-Dawley rats in the response to ketanserin. Pharmacol Biochem Behav. 2013 Dec;114-115:52-7. doi: 10.1016/j.pbb.2013.10.024. Epub 2013 Nov 4. PubMed PMID: 24201045; PubMed Central PMCID: PMC3902122. 6: Aljuffali IA, Brainard BM, Moore JN, Kwon S, Allen D, Robertson TP, Arnold RD. Pharmacokinetic assessment of ketanserin in the horse. J Vet Pharmacol Ther. 2012 Oct;35(5):472-7. doi: 10.1111/j.1365-2885.2011.01346.x. Epub 2011 Nov 18. PubMed PMID: 22091605. 7: Schaafstra L, van Roon EN, Morssink LP, de Vries NK. The effect of maternal ketanserin use on the circulation of the neonate: a prospective, observational study. Eur J Obstet Gynecol Reprod Biol. 2012 May;162(1):11-5. doi: 10.1016/j.ejogrb.2012.01.013. Epub 2012 Feb 19. PubMed PMID: 22349270. 8: Liu C, Zhang GF, Song SW, Cai GJ, Liu WH, Miao CY, Su DF. Effects of ketanserin on endotoxic shock and baroreflex function in rodents. J Infect Dis. 2011 Nov 15;204(10):1605-12. doi: 10.1093/infdis/jir609. Epub 2011 Sep 14. PubMed PMID: 21917879. 9: Peiró AM, Climent L, Zapater P, Horga A, Horga JF. Ketanserin potentiates morphine-induced antinociception mediated by kappa-receptor activation. Pharmacol Res. 2011 Jul;64(1):80-4. doi: 10.1016/j.phrs.2011.02.009. Epub 2011 Mar 21. PubMed PMID: 21420495. 10: Van Peer A, Woestenborghs R, Embrechts L, Heykants J. Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol. Eur J Clin Pharmacol. 1986;31(3):339-42. PubMed PMID: 3792431. 11: Bhatia KS, Szabo ST, Fowler JC, Wetsel WC, Lee TH. Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine. Behav Brain Res. 2011 Sep 30;223(1):227-32. doi: 10.1016/j.bbr.2011.04.045. Epub 2011 May 7. PubMed PMID: 21571009; PubMed Central PMCID: PMC3113440. 12: Coha B, Samardžić P, Dundjer I, Knežević-Praveček M. Cardiac arrhythmia as a side effect of ketanserin therapy in a patient with systemic scleroderma. Acta Dermatovenerol Croat. 2012;20(1):54-6. PubMed PMID: 22507478. 13: Leary WP, Reyes AJ, van der Byl K, Maharaj B. Comparative antihypertensive effects of ketanserin and a ketanserin-hydrochlorothiazide combination administered once daily. J Cardiovasc Pharmacol. 1987;10 Suppl 3:S127-34. PubMed PMID: 2446061. 14: Wang D, Gao Y, Ji H, Hong Y. Topical and systemic administrations of ketanserin attenuate hypersensitivity and expression of CGRP in rats with spinal nerve ligation. Eur J Pharmacol. 2010 Feb 10;627(1-3):124-30. doi: 10.1016/j.ejphar.2009.11.011. Epub 2009 Nov 11. PubMed PMID: 19913012. 15: Muguruza C, Moreno JL, Umali A, Callado LF, Meana JJ, González-Maeso J. Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur Neuropsychopharmacol. 2013 Aug;23(8):852-64. doi: 10.1016/j.euroneuro.2012.10.006. Epub 2012 Nov 21. PubMed PMID: 23176747; PubMed Central PMCID: PMC3586752. 16: Breckenridge A. Ageing, serotonin and ketanserin. Drugs. 1988;36 Suppl 1:44-54. Review. PubMed PMID: 3071462. 17: Bolte AC, van Eyck J, Gaffar SF, van Geijn HP, Dekker GA. Ketanserin for the treatment of preeclampsia. J Perinat Med. 2001;29(1):14-22. PubMed PMID: 11234612. 18: Beretta-Piccoli C, Amstein R, Bertel O, Brunner HR, Bühler FR, Follath F, Solèr M, Vallotton M. Antihypertensive efficacy of ketanserin alone or in combination with a beta-blocker or a diuretic: the Swiss Ketanserin Study. J Cardiovasc Pharmacol. 1987;10 Suppl 3:S119-23. PubMed PMID: 2446058. 19: Symoens J. Ketanserin: a novel cardiovascular drug. Blood Coagul Fibrinolysis. 1990 Jun;1(2):219-24. Review. PubMed PMID: 2130934. 20: Cazzola M, Guidetti E, Sepe J, Assogna G, Lucchetti G, Santangelo G, D'Amato G. Acute respiratory and cardiovascular effects of inhaled ketanserin in chronic obstructive pulmonary disease. A comparative study with intravenously administered ketanserin. Chest. 1990 Apr;97(4):901-5. PubMed PMID: 2182300.

View History

Icosabutate

Icosabutate

NSC745885

NSC745885

Oglufanide TFA

Oglufanide TFA

FSN-00382

FSN-00382

Ketimipramine Free Base

Ketimipramine Free Base

n-MCT

n-MCT